Articles related to PSYCHEDELICS

The use of psychedelics in treating substance use disorder (SUD) is showing promise. A 2012 meta-analysis suggests a favorable probability of reduced alcohol use upon administration of LSD in a controlled context.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

Discover how MDMA-assisted therapy is setting new benchmarks in PTSD treatment, offering clinically meaningful improvements and a strong safety profile.

Discover the advancements in MDD pharmacotherapy that promise to expand treatment options and address unmet needs.

The newly released guidelines for psychedelic-assisted therapy by APPA and BrainFutures provide a comprehensive framework for mental health professionals. Explore the guidelines to understand the benchmarks for safety, ethics, and best practices in this emerging field.

Recent phase 3 clinical trials have demonstrated the eye-opening potential of MDMA in the treatment of PTSD when paired with psychotherapy, providing a new method of patient care.